Tag: Application

Posted on

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

On-monitor to initiate Phase 2 demo in Q1 2023

NEW YORK, Dec. 29, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a affected individual-focused biopharmaceutical company, these days announced that the U.S. Food stuff and Drug Administration (Food and drug administration) has accepted an Investigational New Drug (IND) software for the firm’s HT-001 therapeutic for the treatment for rash and pores and skin issues associated with epidermal growth factor receptor (EGFR) inhibitor treatment. EGFR inhibitors are critical therapeutic agents for the remedy of non-modest cell lung most cancers (NSCLC), pancreatic most cancers, colorectal most cancers, squamous-cell carcinoma of the head and neck, and breast cancer.

(PRNewsfoto/Hoth Therapeutics Inc.)

(PRNewsfoto/Hoth Therapeutics Inc.)

“We are enthusiastic to commence our demo and convey hope to sufferers who are struggling.  With no certain therapy at present permitted for the therapy of pores and skin toxicities linked with EGFRi therapies, this trial provides us a single stage nearer to a new treatment method option for underserved most cancers people,” said Robb Knie, CEO of Hoth Therapeutics, Inc. “We appear ahead to advancing HT-001 into the medical section as we believe that this novel therapeutic will be a critical cure in the onco-dermatology area. We foresee starting our Section 2a trial in Q1 of 2023.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical corporation focused to producing ground breaking, impactful, and ground-breaking treatment options with a purpose to improve affected individual good quality of lifetime. We are a catalyst in early-phase pharmaceutical exploration and advancement, elevating medicines from the bench to pre-scientific and scientific testing. Utilizing a individual-centric tactic, we collaborate and partner with a group of researchers, clinicians, and important opinion leaders to search for out and look into therapeutics that maintain immense prospective to produce breakthroughs and diversify procedure possibilities.  To find out extra, please check out https://ir.hoththerapeutics.com/.

Ahead-Searching Assertion

This push release consists of ahead-seeking statements primarily based on Hoth’s present expectations which might represent ahead-hunting statements for the applications of the protected harbor provisions less than the Private Securities Litigation Reform Act of 1995 and other federal securities regulations, and are matter to sizeable threats, uncertainties and assumptions. These statements issue Hoth’s enterprise strategies the timing of regulatory submissions the means to obtain and manage regulatory acceptance of current solution candidates and any other product candidates Hoth might develop, and the labeling under any acceptance Hoth may possibly get hold of the timing and prices of medical trials, the timing and expenditures of other fees market place acceptance of Hoth’s solutions the supreme impression of the present-day Coronavirus pandemic, or any other wellbeing epidemic, on Hoth’s organization, its clinical trials, its investigation courses, healthcare units or the world overall economy as a total Hoth’s intellectual house Hoth’s reliance on third social gathering corporations Hoth’s aggressive place Hoth’s sector surroundings Hoth’s anticipated monetary and running final results, such as anticipated resources of revenues Hoth’s assumptions pertaining to the size of the offered industry, benefits of Hoth’s goods, products pricing, timing of products launches management’s expectation with regard to long term acquisitions statements with regards to Hoth’s aims, intentions, strategies and expectations, which includes the introduction of new products and solutions and marketplaces and Hoth’s hard cash wants and funding plans. There are a selection of components that could trigger precise functions to differ materially from those people indicated by this kind of forward-seeking statements. You should not location undue reliance on these forward-searching statements, which incorporate words these as “could,” “consider,” “foresee,” “intend,” “estimate,” “expect,” “may perhaps,” “carry on,” “forecast,” “likely,” “job” or very similar terms, versions of this sort of conditions or the detrimental of individuals phrases. Even though Hoth believes that the expectations reflected in the forward-on the lookout statements are fair, Hoth cannot ensure this kind of outcomes. Hoth may perhaps not realize its anticipations, and its beliefs could not verify proper. Genuine outcomes might vary materially from individuals indicated by these ahead-seeking statements as a outcome of different crucial aspects, including, without limitation, sector problems and the components explained in the portion entitled “Threat Factors” in Hoth’s most new Annual Report on Sort 10-K and Hoth’s other filings produced with the U.S. Securities and Exchange Commission. All such statements talk only as of the day of this press launch. Consequently, ahead-hunting statements should really be regarded entirely as Hoth’s present-day ideas, estimates, and beliefs. Hoth are unable to assure potential final results, functions, levels of activity, efficiency or achievements. Hoth does not undertake and exclusively declines any obligation to update or revise any forward-seeking statements to replicate new info, potential functions or instances or to reflect the occurrences of unanticipated functions, except as may well be necessary by applicable law.

Trader Get in touch with:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Cellular phone: (678) 570-6791

Cision

Cision

Check out authentic information to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-food and drug administration-acceptance-of-ind-application-for-ht-001-for-the-remedy-of-most cancers-diseases-linked-with-epidermal-growth-factor-receptor-egfr-inhibitor-therapy-301711012.html

Resource Hoth Therapeutics, Inc.

Posted on

A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine

A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine

  • Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76.

    Article 
    PubMed 

    Google Scholar     

  • Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ. 2017;359:j4792.

    Article 
    PubMed 

    Google Scholar     

  • Hirschfeld DJ. Trump Declares Opioid Crisis a ‘Health Emergency’ Requests no Funds The New York Times; 2017.


    Google Scholar     

  • Hollmann MW, Rathmell JP, Lirk P. Optimal postoperative pain management: redefining the role for opioids. Lancet. 2019;393(10180):1483–5.

    Article 
    PubMed 

    Google Scholar     

  • Silva BM, Rodrigues JJ, de la Torre DI, Lopez-Coronado M, Saleem K. Mobile-health: A review of current state in 2015. J Biomed Inform. 2015;56:265–72.

    Article 
    PubMed 

    Google Scholar     

  • Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. Eur Heart J. 2016;37(18):1428–38.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017;152(6):e170504.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hamnvik OR, Alford DP, Ryan CT, Hardesty IT, Drazen JM. NEJM Knowledge+ Pain Management and Opioids – A New Adaptive Learning Module. N Engl J Med. 2019;380(16):1576–7.

    Article 
    PubMed 

    Google Scholar     

  • Babu KM, Brent J, Juurlink DN. Prevention of Opioid Overdose. N Engl J Med. 2019;380(23):2246–55.

    Article 
    PubMed 

    Google Scholar     

  • Colloca L, Barsky AJ. Placebo and Nocebo Effects. N Engl J Med. 2020;382(6):554–61.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Benedetti F. Placebo analgesia. Neurol Sci. 2006;27(2):100–2.

    Article 

    Google Scholar     

  • Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol. 2004;3(11):679–84.

    Article 
    PubMed 

    Google Scholar     

  • Hack TF, Degner LF, Parker PA, Team SC. The communication goals and needs of cancer patients: a review. Psychooncology. 2005;14(10):831–47.

    Article 
    PubMed 

    Google Scholar     

  • Del Re AC, Fluckiger C, Horvath AO, Symonds D, Wampold BE. Therapist effects in the therapeutic alliance-outcome relationship: a restricted-maximum likelihood meta-analysis. Clin Psychol Rev. 2012;32(7):642–9.

    Article 
    PubMed 

    Google Scholar     

  • Epstein R, Street RL. Patient-centered communication in cancer care: promoting healing and reducing suffering: National Cancer Institute. Bethesda: US Department of Health and Human Services, National Institutes of Health; 2007.


    Google Scholar     

  • Baker PN, van der Meulen JH, Lewsey J, Gregg PJ. The role of pain and function in determining patient satisfaction after total knee replacement. Data from the National Joint Registry for England and Wales. J Bone Joint Surg Br. 2007;89(7):893–900.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • World Health O. ICD-10 : international statistical classification of diseases and related health problems : tenth revision. 2nd ed. Geneva: World Health Organization; 2004.


    Google Scholar     

  • Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Younger J, Gandhi V, Hubbard E, Mackey S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials. 2012;9(6):767–76.

    Article 
    PubMed 

    Google Scholar     

  • Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60.

    Article 
    PubMed 

    Google Scholar     

  • Booth RG, Strudwick G, McBride S, O’Connor S, Solano López AL. How the nursing profession should adapt for a digital future. BMJ. 2021;373:n1190.

    Article 
    PubMed Central 

    Google Scholar     

  • Fairbrother P, Ure J, Hanley J, McCloughan L, Denvir M, Sheikh A, et al. Telemonitoring for chronic heart failure: the views of patients and healthcare professionals – a qualitative study. J Clin Nurs. 2014;23(1-2):132–44.

    Article 
    PubMed 

    Google Scholar     

  • Barello S, Triberti S, Graffigna G, Libreri C, Serino S, Hibbard J, et al. eHealth for Patient Engagement: A Systematic Review. Front Psychol. 2015;6:2013.

    PubMed 

    Google Scholar     

  • Eaton L, Walsh C, Magnuson T, Schweitzer M, Lidor A, Nguyen H, et al. On-line bariatric surgery information session as effective as in-person information session. Surg Obes Relat Dis. 2012;8(2):225–9.

    Article 
    PubMed 

    Google Scholar     

  • Heikkinen K, Leino-Kilpi H, Vahlberg T, Salanterä S. Ambulatory orthopaedic surgery patients’ symptoms with two different patient education methods. Int J Orthop Trauma Nurs. 2012;16(1):13–20.

    Article 

    Google Scholar     

  • Matthew DA. The use of a computer website prior to scheduled surgery (a pilot study): impact on patient information, acquisition, anxiety level, and overall satisfaction with anesthesia care. AANA J. 2005;73(1):29.


    Google Scholar     

  • D’Haese PF, Pallavaram S, Li R, Remple MS, Kao C, Neimat JS, et al. CranialVault and its CRAVE tools: a clinical computer assistance system for deep brain stimulation (DBS) therapy. Med Image Anal. 2012;16(3):744–53.

    Article 
    PubMed 

    Google Scholar     

  • de Visser H, Watson MO, Salvado O, Passenger JD. Progress in virtual reality simulators for surgical training and certification. Med J Aust. 2011;194(4):S38–40.

    PubMed 

    Google Scholar     

  • Neuprez A, Neuprez AH, Kaux J-F, Kurth W, Daniel C, Thirion T, et al. Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. Cartilage. 2018;9(2):127–39.

    Article 
    PubMed 

    Google Scholar     

  • Klimek M, Büchele G, Rehm M, Beyersmann J, Günther KP, Brenner H, et al. Long-term mortality of patients with osteoarthritis after joint replacement: Prognostic value of pre-and postoperative pain and function. Athritis Care Res. 2021;0(0):1–7. https://doi.org/10.1002/acr.24808.

    Article 
    CAS 

    Google Scholar     

  • Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. N Engl J Med. 2015;373(1):8–9.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain. 2001;90(3):205–15.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3(70):70ra14. https://doi.org/10.1126/scitranslmed.3001244.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218ra5).

  • Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature. 1984;312(5996):755–6.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Moore RA, Cai N, Skljarevski V, Tolle TR. Duloxetine use in chronic painful conditions–individual patient data responder analysis. Eur J Pain. 2014;18(1):67–75.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1-3):1–8.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Colloca L. The Placebo Effect in Pain Therapies. Annu Rev Pharmacol Toxicol. 2019;59:191–211.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Elsenbruch S, Kotsis V, Benson S, Rosenberger C, Reidick D, Schedlowski M, et al. Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders. Pain. 2012;153(2):382–90.

    Article 
    PubMed 

    Google Scholar     

  • Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5(12):e15591.

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar     

  • Timmers T, Janssen L, Kool RB, Kremer JA. Educating Patients by Providing Timely Information Using Smartphone and Tablet Apps: Systematic Review. J Med Internet Res. 2020;22(4):e17342.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Klinger R, Colloca L, Bingel U, Flor H. Placebo analgesia: clinical applications. Pain. 2014;155(6):1055–8.

    Article 
    PubMed 

    Google Scholar     

  • Colloca L, Jonas WB, Killen J, Miller FG, Shurtleff D. Reevaluating the placebo effect in medical practice. Z Psychol. 2014;222(3):124–7.

    PubMed 
    PubMed Central 

    Google Scholar     

  • Benedetti F. Placebo Effects. Understanding the mechanisms in health and disease. Oxford: Oxford University Press; 2014.

    Book 

    Google Scholar     

  • Colloca L, Miller FG. Harnessing the placebo effect: the need for translational research. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1922–30.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191–204.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Miller FG, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioeth. 2009;9(12):39–47.

    Article 
    PubMed 

    Google Scholar     

  • Schedlowski M, Enck P, Rief W, Bingel U. Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol Rev. 2015;67(3):697–730.

    Article 
    PubMed 

    Google Scholar     

  • Crum A, Zuckerman B. Changing Mindsets to Enhance Treatment Effectiveness. JAMA. 2017;317(20):2063–4.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–90.

    Article 
    PubMed 

    Google Scholar     

  • Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain. 2005;114(1-2):3–6.

    Article 
    PubMed 

    Google Scholar     

  • Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307(6):567–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Colloca L. How do placebo effects and patient-clinician relationships influence behaviors and clinical outcomes? Pain Rep. 2019;4(3):e758.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ashton-James CE, Forouzanfar T, Costa D. The contribution of patients’ presurgery perceptions of surgeon attributes to the experience of trust and pain during third molar surgery. Pain Rep. 2019;4(3):e754.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Henry SG, Matthias MS. Patient-Clinician Communication About Pain: A Conceptual Model and Narrative Review. Pain Med. 2018;19(11):2154–65.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Volkow ND, Collins FS. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017;377(4):391–4.

    Article 
    PubMed 

    Google Scholar     

  • White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469–79.

    Article 
    PubMed 

    Google Scholar     

  • Wolford ML, Palso K, Bercovitz A. Hospitalization for total hip replacement among inpatients aged 45 and over: United States, 2000-1010: US Department of Health and Human Services, Centers for Disease Control and …; 2015.

  • Arthrose K-IR. Gesundheitsberichterstattung des Bundes. Berlin: RKI; 2013.


    Google Scholar     

  • Darley JM, Fazio RH. Expectancy confirmation processes arising in the social interaction sequence. Am Psychol. 1980;35(10):867–81.

    Article 

    Google Scholar     

  • Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50(2):133–49.

    Article 

    Google Scholar     

  • Klinger R, Krug F, Goßmann M, Damzog U, Dahme B, Bruch H-P. Das perioperative Schmerz- und Befindlichkeitsinventar: Ein Fragebogen zur Erfassung der perioperativen Lebensqualität. Der Schmerz. 1999;13:86.


    Google Scholar     

  • Flor H, Rudy TE, Birbaumer N, Streit B, Schugens MM. The applicability of the West Haven-Yale multidimensional pain inventory in German-speaking countries. Data on the reliability and validity of the MPI-D. Schmerz. 1990;4(2):82–7.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Lowe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122(1-2):86–95.

    Article 
    PubMed 

    Google Scholar     

  • Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol. 1997;24(4):779–81.

    PubMed 
    CAS 

    Google Scholar     

  • Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.

    Article 
    PubMed 

    Google Scholar     

  • Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open. 2012;2(1):e000435.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kim SS, Kaplowitz S, Johnston MV. The effects of physician empathy on patient satisfaction and compliance. Eval Health Prof. 2004;27(3):237–51.

    Article 
    PubMed 
    CAS 

    Google Scholar     

  • Sim I. Mobile Devices and Health. N Engl J Med. 2019;381(10):956–68.

    Article 
    PubMed 

    Google Scholar     

  • Bortz J, Schuster C. Statistik für Human-und Sozialwissenschaftler: Limitierte Sonderausgabe. Berlin: Springer-Verlag; 2011.


    Google Scholar     

    • Posted on

    UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

    UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
    Veru Inc.

    Veru Inc.

    MIAMI, July 25, 2022 (Globe NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical firm concentrated on developing novel medicines for COVID-19 and other viral and ARDS-related ailments and for the administration of breast and prostate cancers, these days declared that the United Kingdom’s (UK’s) Medicines and Healthcare Solutions Regulatory Agency (MHRA) considers that the currently available security and efficacy info will assist an expedited overview of the promoting authorization application for the Company’s sabizabulin treatment method in hospitalized COVID-19 sufferers at large risk for Acute Respiratory Distress Syndrome (ARDS) when the software is submitted.

    “We are happy that the MHRA has agreed to guidance the expedited overview of our sabizabulin British isles promoting authorization submission. With this choice, we prepare to commence towards the submission of our application as soon as achievable,” stated Mitchell Steiner, M.D., Chairman, President, and Main Govt Officer of Veru. “COVID infections are sharply increasing in the United kingdom. Regrettably, the death fee in hospitalized patients with reasonable to severe COVID-19 who are at chance for ARDS remains unacceptably significant with existing regular of treatment. By decreasing fatalities in hospitalized COVID-19 people, sabizabulin has terrific potential to participate in a important job in the struggle in opposition to COVID-19 in the British isles and somewhere else.”

    About Veru Inc.
    Veru is a biopharmaceutical company centered on acquiring novel medications for COVID-19 and other viral and ARDS-similar illnesses and for the management of breast and prostate cancers.

    Infectious ailment program:

    The Firm has concluded a good Section 3 COVID-19 analyze in hospitalized moderate to serious COVID-19 people at high chance for ARDS.

    A double-blind, randomized, placebo-managed Section 3 COVID-19 clinical demo was performed in around 210 hospitalized COVID-19 patients with reasonable to intense COVID (≥ WHO 4-supplemental oxygen) at significant chance for ARDS and death. The key endpoint was the proportion of fatalities by Working day 60. Based on a prepared interim assessment of the very first 150 sufferers randomized, the Impartial Knowledge Checking Committee unanimously halted the study for frustrating efficacy and safety. Cure with sabizabulin 9mg when day-to-day, an oral, first-in-class, new chemical entity, microtubule disruptor that has twin anti-inflammatory and antiviral houses, resulted in a clinically meaningful and statistically substantial 55.2{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} relative reduction in deaths. On June 7, 2022, the Firm submitted a ask for for unexpected emergency use authorization to Fda. On July 6, 2022, the Corporation introduced the publication of the Section 3 COVID-19 demo outcomes assessing the efficacy and security of oral sabizabulin in The New England Journal of Drugs Evidence®.

    Oncology plan:

    The Company’s late-phase breast most cancers progress portfolio comprises enobosarm, a selective androgen receptor focusing on agonist, and sabizabulin.

    Recent scientific tests on the two drugs incorporate:

    • Enrolling Phase 3 ARTEST review of enobosarm in androgen receptor optimistic, estrogen receptor positive, and human epidermal advancement element receptor two detrimental (AR+ ER+ HER2-) metastatic breast most cancers with AR ≥ 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (third-line metastatic placing), and which has been granted Fast Track designation by the Fda.

    • Enrolling Phase 3 ENABLAR-2 research of enobosarm + abemaciclib (a CDK 4/6 inhibitor) combination in AR+ ER+ HER2- metastatic breast cancer with AR ≥ 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (2nd-line metastatic placing). The Organization and Eli Lilly and Enterprise have entered into a clinical research collaboration and provide arrangement for the ENABLAR-2 review. Lilly will supply Verzenio® (abemaciclib).

    • Planned Section 2b research of sabizabulin in AR+ ER+ HER2- metastatic breast cancer with AR < 40{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} expression (third-line metastatic setting).

    Veru’s late-stage prostate cancer portfolio comprises sabizabulin, VERU-100, a long-acting GnRH antagonist, and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.

    Current studies on these drugs include:

    • Enrolling Phase 3 VERACITY study in metastatic castration and androgen receptor targeting agent resistant prostate cancer prior to IV chemotherapy.

    • Enrolling Phase 2 dose-finding study of VERU-100 in advanced hormone sensitive prostate cancer.

    • Planned Phase 2b study of zuclomiphene citrate to treat hot flashes in men with advanced prostate cancer undergoing androgen deprivation therapy.

    Commercial sexual health program, Urev, has 2 FDA approved products:

    • ENTADFI™ (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia, for which commercialization launch plans are underway.

    • FC2 Female Condom® (internal condom), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections which is sold in the U.S. and globally.

    Forward-Looking Statements
    The statements in this release that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding: whether and when the Company will receive an emergency use authorization or any approval from FDA or MHRA or from any other regulatory authority outside the U.S. for sabizabulin for certain COVID-19 patients whether and when sabizabulin will become an available treatment option for certain COVID-19 patients in the U.S., UK or anywhere else outside the U.S. whether and when the Company will submit a marketing authorization application for sabizabulin to MHRA’ whether the Company will have sufficient supply of sabizabulin to meet demand, if an emergency use authorization or other approval is granted in the U.S. or in any other country whether the Company will secure any advance purchase agreement with the U.S. government or any foreign government whether the current and future clinical development and results will demonstrate sufficient efficacy and safety and potential benefits to secure FDA approval of the Company’s drug candidates and companion diagnostic whether the drug candidates will be approved for the targeted line of therapy the anticipated design and scope of clinical studies and FDA acceptance of such design and scope whether any regulatory pathways, including the accelerated Fast Track designations, to seek FDA approval for sabizabulin, enobosarm or any of the Company’s drug candidates are or continue to be available whether the expected commencement and timing of the Company’s clinical studies, including the Phase 3 ARTEST study, the Phase 3 ENABLAR-2 study, the sabizabulin monotherapy Phase 2b clinical study for 3rd line treatment of metastatic breast cancer, the Phase 2 registration clinical study for VERU-100, and the development of the companion diagnostic will be met when clinical results from the ongoing clinical studies will be available, whether sabizabulin, enobosarm, VERU-100, zuclomiphene, and ENTADFI will serve any unmet need or, what dosage, if any, might be approved for use in the U.S. or elsewhere, and also statements about the potential, timing and efficacy of the rest of the Company’s development pipeline, and the timing of the Company’s submissions to FDA and MHRA and FDA’s and MHRA’s review of all such submissions whether the companion diagnostic for enobosarm will be developed successfully or be approved by the FDA for use and whether and when ENTADFI will be commercialized successfully. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development the ability to enroll sufficient numbers of subjects in clinical studies and the ability to enroll subjects in accordance with planned schedules the ability to fund planned clinical development the timing of any submission to the FDA, MHRA or any other regulatory authority and any determinations made by the FDA, MHRA or any other regulatory authority the possibility that as vaccines and other antiviral medicines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated government entities possibly taking actions that directly or indirectly have the effect of limiting opportunities for sabizabulin as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments the Company’s existing products and any future products, if approved, possibly not being commercially successful the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical studies, supply chain and other third-party providers, commercial efforts, and business development operations the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations demand for, market acceptance of, and competition against any of the Company’s products or product candidates new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes risks relating to the Company’s development of its own dedicated direct to patient telemedicine and telepharmacy services platform, including the Company’s lack of experience in developing such a platform, potential regulatory complexity, and development costs the Company’s ability to protect and enforce its intellectual property the potential that delays in orders or shipments under government tenders or the Company’s U.S. prescription business relating to the FC2 female condom could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector for its FC2 female condom the concentration of accounts receivable with our largest customers and the collection of those receivables the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply any of its product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions costs and other effects of litigation, including product liability claims the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives the Company’s ability to successfully integrate acquired businesses, technologies or products and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the fiscal year ended September 30, 2021 and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors. The Company disclaims any intent or obligation to update these forward-looking statements.

    Verzenio® is a registered trademark of Eli Lilly and Company

    NEJM Evidence® is a registered trademark of the Massachusetts Medical Society

    Investor and Media Contact:

    Samuel Fisch
    Executive Director, Investor Relations and Corporate Communications
    Email: veruinvestor@verupharma.com